cisplatin + recombinant granulocyte-colony stimulating factor + vindesine

This is a combination chemotherapy regimen consisting of three agents:

• Cisplatin is a platinum-based antineoplastic agent that acts as an alkylating agent, cross-linking DNA and inhibiting DNA replication and transcription, leading to cell death. It is widely used in the treatment of various cancers.
• Vindesine is a vinca alkaloid that inhibits microtubule formation in mitotic spindle fibers, thereby arresting cell division at metaphase.
• Recombinant granulocyte-colony stimulating factor (rG-CSF) is a biologic cytokine therapy used to stimulate the production of neutrophils from the bone marrow, reducing the risk and duration of chemotherapy-induced neutropenia.

This specific combination has been studied primarily for advanced non-small-cell lung cancer (NSCLC), where rG-CSF enables higher dose intensity and shorter cycle intervals by mitigating neutropenia caused by cisplatin and vindesine. The regimen has demonstrated notable response rates in clinical trials for NSCLC.